For anyone who has lingering doubts about the basic science,clinical science and FDA regulatory environment conducive to the imminent FDA approval of DCVAX-L ,this paper(Rago 2018) by a scientist( John Hopkins educated and trained) ,who knows the biotechnology industry ,is required reading.
I recommend you read it carefully ,if you patience is presently strained or you question the wisdom of your investment.His reflections on the mechanism of clinical efficacy of this second generation technology, based on the science of Nobel laeurate (2011) W .Steinman, is encouraging.